CDK4 and breast cancer: Also, CCL5 was found to be increased, and chemokine/chemokine receptor signature was enriched after CDK4/6 inhibitor treatment in a phase II study in HR+/HER2− breast cancer patients [53] and in a mouse model of mammary tumors [49], which are in agreement with our findings.